The relationship between AD, Aβ and tau pathology is poorly understood, but recent results suggest that tau is not simply a downstream process of Aβ aggregation [14], and substances that inhibit tau aggregate formation might be interesting for AD therapy development. Here, MAPT is linked to Alzheimer disease.